Title:
CROSS-LINKED MEDICATION FOR TREATMENT OF CORONAVIRAL INFECTION AND METHOD OF TREATMENT
Document Type and Number:
WIPO Patent Application WO/2021/180251
Kind Code:
A1
Abstract:
A cross-linked medication containing nitazoxanide or tizoxanide and ribavirin, and uses thereof in the treatment or prevention of coronaviral infection. The present cross-linked medication is particularly effective in the treatment of disease (Covid-19) caused by SARS-CoV-2.
Inventors:
LI CHIANG J (US)
Application Number:
PCT/CN2021/092693
Publication Date:
September 16, 2021
Filing Date:
May 10, 2021
Export Citation:
Assignee:
1GLOBE BIOMEDICAL CO LTD (CN)
International Classes:
A61K31/426; A61K31/7056; A61K45/06; A61P11/00; A61P31/14; A61P31/16
Domestic Patent References:
| WO2004100980A1 | 2004-11-25 |
Foreign References:
| CN101903026A | 2010-12-01 | |||
| EP3078377A2 | 2016-10-12 | |||
| CN108348470A | 2018-07-31 | |||
| US20160228415A1 | 2016-08-11 |
Other References:
ROSSIGNOL JEAN-FRANÇOIS: "Nitazoxanide, a New Drug Candidate for the Treatment of Middle East Respiratory Syndrome Coronavirus.", JOURNAL OF INFECTION AND PUBLIC HEALTH, vol. 9, no. 3, 31 December 2016 (2016-12-31), pages 227 - 230, XP029547996, ISSN: 1876-0341, DOI: 10.1016/j.jiph.2016.04.001
Download PDF:
Previous Patent: PREPARATION FOR INHIBITING CANDIDA ALBICANS
Next Patent: NOVEL APPLICATION AND MANUFACTURING METHOD FOR HYALURONIC ACID FRAGMENT
Next Patent: NOVEL APPLICATION AND MANUFACTURING METHOD FOR HYALURONIC ACID FRAGMENT